These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 7674266)

  • 21. APC-resistance and Mnl I genotype (Gln 506) of coagulation factor V are rare in Japanese population.
    Takamiya O; Ishida F; Kodaira H; Kitano K
    Thromb Haemost; 1995 Sep; 74(3):996. PubMed ID: 8571340
    [No Abstract]   [Full Text] [Related]  

  • 22. [Activated protein C resistance as a cause of thrombophilia].
    Ruiz-Argüelles GJ
    Rev Invest Clin; 1996; 48(3):223-9. PubMed ID: 8966383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factor V Leiden mutation and antiphospholipid syndrome: risk factors for atherosclerotic and arterial thromboembolic disease.
    Thakor AS; Shah D; Miller F; Gaunt ME
    J Vasc Interv Radiol; 2009 Aug; 20(8):1097-8. PubMed ID: 19574060
    [No Abstract]   [Full Text] [Related]  

  • 24. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden.
    Weitz IC; Israel VK; Liebman HA
    Cancer; 1997 May; 79(10):2024-7. PubMed ID: 9149031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Leiden, G20210A mutations in prothrombin gene and antiphospholipid antibodies in systemic lupus erythematosus and antiphospholipid syndrome].
    Reshetniak TM; Patrushev LI; Stukacheva EA; Miroshnikov AI; Tikhonova TL; Nasonov EL; Alekberova ZS
    Ter Arkh; 2000; 72(5):34-8. PubMed ID: 11109617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inherited homozygous resistance to activated protein C.
    Villa P; Aznar J; Jorquera J; Mira Y; Vayá A; Fernández MA
    Thromb Haemost; 1995 Aug; 74(2):794-5. PubMed ID: 8585025
    [No Abstract]   [Full Text] [Related]  

  • 27. Predisposition to thrombosis by a factor V mutation causing hereditary resistance to activated protein C.
    Press RD; Goodnight SH
    West J Med; 1995 May; 162(5):450-2. PubMed ID: 7785262
    [No Abstract]   [Full Text] [Related]  

  • 28. The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein C resistance.
    Kirschbaum NE; Foster PA
    Thromb Haemost; 1995 Sep; 74(3):874-8. PubMed ID: 8571314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and clinical manifestations of activated protein C resistance and factor V Leiden in young patients with venous thromboembolic disease in Spain.
    Olave T; Cornudella R; Homs C; Azaceta G; Tirado I; Gutierrez M
    Haematologica; 1998 Apr; 83(4):378-80. PubMed ID: 9592991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical features in 36 patients homozygous for the ARG 506-->GLN factor V mutation.
    Emmerich J; Alhenc-Gelas M; Aillaud MF; Juhan-Vague I; Jude B; Garcin JM; Dreyfus M; de Moerloose P; Le Querrec A; Priollet P; Berruyer M; Vallantin X; Wolf M; Aiach M; Fiessinger JN
    Thromb Haemost; 1997 Apr; 77(4):620-3. PubMed ID: 9134631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activated protein C resistance: molecular mechanisms.
    Griffin JH; Heeb MJ; Kojima Y; Fernández JA; Kojima K; Hackeng TM; Greengard JS
    Thromb Haemost; 1995 Jul; 74(1):444-8. PubMed ID: 8578503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular genetics of thrombophilia: factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulable state.
    Dahlbäck B
    J Lab Clin Med; 1995 May; 125(5):566-71. PubMed ID: 7738422
    [No Abstract]   [Full Text] [Related]  

  • 33. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency.
    Zöller B; Holm J; Svensson P; Dahlbäck B
    Thromb Haemost; 1996 Feb; 75(2):270-4. PubMed ID: 8815575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Familial coexistence of primary antiphospholipid syndrome and factor VLeiden.
    Schütt M; Klüter H; Hagedorn-Greiwe M; Fehm HL; Wiedemann GJ
    Lupus; 1998; 7(3):176-82. PubMed ID: 9607641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Primary antiphospholipid syndrome in combination with heterozygous mutation in prothrombin (G20210A) gene: a case report].
    Tikhonova TL; Kovalenko TF; Patrushev LI; Mach ES; Reshetniak TM
    Klin Med (Mosk); 2002; 80(10):66-9. PubMed ID: 12471843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to activated protein C as a risk factor of stroke in a thalassemic patient.
    Giordano P; Sabato V; Schettini F; De Mattia D; Iolascon A
    Haematologica; 1997; 82(6):698-700. PubMed ID: 9499670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of phenotypic activated protein C resistance (APCR) in venous thromboembolic patients.
    Marzo C; Araguás C; Gómez-Arbonés J; Ramírez S
    Haematologica; 1998 Apr; 83(4):377-8. PubMed ID: 9592990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
    Montaruli B; Schinco P; Pannocchia A; Giorgianni A; Borchiellini A; Tamponi G; Pileri A
    Thromb Haemost; 1997 Sep; 78(3):1042-8. PubMed ID: 9308751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activated protein C resistance caused by factor V Arg 506-->Gln mutation has no role in thrombotic manifestations of Behçet's disease.
    Lesprit P; Wechsler B; Piette JC; Du-Boutin LT; Godeau P; Alhenc-Gelas M; Aiach M
    Ann Rheum Dis; 1995 Oct; 54(10):860. PubMed ID: 7492231
    [No Abstract]   [Full Text] [Related]  

  • 40. Ischaemic stroke in infancy and childhood: role of the Arg506 to Gln mutation in the factor V gene.
    Nowak-Göttl U; Sträter R; Dübbers A; Oleszuk-Raschke K; Vielhaber H
    Blood Coagul Fibrinolysis; 1996 Oct; 7(7):684-8. PubMed ID: 8958390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.